Targeting of the MNK-eIF4E axis in blast crisis Chronic myeloid leukemia inhibits leukemia stem cell function

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 25, 2013, Pages

  Lim, Sharon ^a   Saw, Tzuen Yih ^a   Zhang, Min ^b   Janes, Matthew R ^b   Nacro, Kassoum ^c   Hill, Jeffrey ^c   Lim, An Qi ^a   Chang, Chia Tien ^a   Fruman, David A ^b   Rizzieri, David A ^d   Tan, Soo Yong ^e   Fan, Hung ^b   Chuah, Charles T H ^a,f   Ong, S Tiong ^a,d,f,g  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Agency for Science   (Singapore)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Department of Pathology ^*  (United States)

^f SINGAPORE GENERAL HOSPITAL   (Singapore)

^g DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Biomarker; Cancer stem cell; Wnt pathway; Xenograft

Indexed keywords

BCR ABL PROTEIN; BETA CATENIN; INITIATION FACTOR 4E;

ARTICLE; BLAST CELL CRISIS; CANCER INHIBITION; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT GM; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

BIOMARKER; CANCER STEM CELL; WNT PATHWAY; XENOGRAFT;

ANILINE COMPOUNDS; ANIMALS; BETA CATENIN; BLAST CRISIS; BONE MARROW CELLS; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED NOD; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PURINES; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EUKARYOTA;

EID: 84879316511     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1301838110     Document Type: Article

References (54)

1. Quintás-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113(8):1619-1630.
2. Hochhaus A, et al.; IRIS Investigators (2009) vaSix-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23(6):1054-1061.
3. Radich JP (2007) The Biology of CML blast crisis. Hematology (Am Soc Hematol Educ Program) 384-391.
4. Jamieson CH, et al. (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351(7):657-667.
5. Perrotti D, Jamieson C, Goldman J, Skorski T (2010) Chronic myeloid leukemia: Mechanisms of blastic transformation. J Clin Invest 120(7):2254-2264.
6. Abrahamsson AE, et al. (2009) Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA 106(10):3925-3929.
7. Huntly BJ, et al. (2004) MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. vsCancer Cell 6(6):587-596.
8. Zhang M, et al. (2008) Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol 28(20):6496-6509.
9. Prabhu S, et al. (2007) A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene 26(8):1188-1200.
10. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST (2003) Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 63(18):5716-5722.
11. Hagner PR, Schneider A, Gartenhaus RB (2010) Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 115(11):2127-2135.
12. Topisirovic I, et al. (2003) Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol 23(24):8992-9002.
13. Gingras AC, Raught B, Sonenberg N (1999) eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68:913-963.
14. Sonenberg N, Dever TE (2003) Eukaryotic translation initiation factors and regulators. Curr Opin Struct Biol 13(1):56-63.
15. Wendel HG, et al. (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev 21(24):3232-3237.
16. Ruggero D, et al. (2004) The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10(5):484-486.
17. Mamane Y, et al. (2004) eIF4E-from translation to transformation. Oncogene 23(18):3172-3179.
18. Mamane Y, et al. (2007) Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE 2(2):e242.
19. Larsson O, et al. (2007) Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res 67(14):6814-6824.
20. Ueda T, et al. (2010) Combined deficiency for MAP kinase-interacting kinase 1 and 2(Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci USA 107 (32):13984-13990.
21. Konicek BW, et al. (2011) Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res 71(5):1849-1857.
22. Furic L, et al. (2010) eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA 107(32):14134-14139.
23. Manz MG, Miyamoto T, Akashi K, Weissman IL (2002) Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci USA 99(18):11872-11877.
24. Karni R, Gus Y, Dor Y, Meyuhas O, Levitzki A (2005) Active Src elevates the expression of beta-catenin by enhancement of cap-dependent translation. Mol Cell Biol 25(12):5031-5039.
25. Hovanes K, et al. (2001) Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 28(1):53-57.
26. van Noort M, Weerkamp F, Clevers HC, Staal FJ (2007) Wnt signaling and phosphorylation status of beta-catenin: Importance of the correct antibody tools. Blood 110(7):2778-2779.
27. Culjkovic B, et al. (2008) The eIF4E RNA regulon promotes the Akt signaling pathway. J Cell Biol 181(1):51-63.
28. Fang D, et al. (2007) Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 282(15):11221-11229.
29. Knauf U, Tschopp C, Gram H (2001) Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol 21(16):5500-5511.
30. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R (2004) Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24(15):539-6549.
31. Lepourcelet M, et al. (2004) Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5(1):91-102.
32. Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96(10):3343-3356.
33. Chu S, Holtz M, Gupta M, Bhatia R (2004) BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103(8):3167-3174.
34. Karaman MW, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26(1):127-132.
35. Bain J, et al. (2007) The selectivity of protein kinase inhibitors: A further update. Biochem J 408(3):297-315.
36. Sakanaka C (2002) Phosphorylation and regulation of beta-catenin by casein kinase I epsilon. J Biochem 132(5):697-703.
37. Tsai IC, et al. (2007) Disease-associated casein kinase I delta mutation may promote adenomatous polyps formation via a Wnt/beta-catenin independent mechanism. Int J Cancer 120(5):1005-1012.
38. Greer YE, Rubin JS (2011) Casein kinase 1 delta functions at the centrosome to mediate Wnt-3a-dependent neurite outgrowth. J Cell Biol 192(6):993-1004.
39. O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ (2011) Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 17(2):212-221.
40. Reya T, et al. (2003) A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423(6938):409-414.
41. Wheater MJ, Johnson PW, Blaydes JP (2010) The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biol Ther 10(7):728-735.
42. Korneeva NL, et al. (2010) Mnk mediates integrin α6β4- dependent eIF4E phosphorylation and translation of VEGF mRNA. Mol Cancer Res 8(12):1571-1578.
43. Hay N (2010) Mnk earmarks eIF4E for cancer therapy. Proc Natl Acad Sci USA 107(32):13975-13976.
44. Silva RL, Wendel HG (2008) MNK, EIF4E and targeting translation for therapy. Cell Cycle 7(5):553-555.
45. Bianchini A, et al. (2008) Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 29(12):2279-2288.
46. Scheper GC, Proud CG (2002) Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation? Eur J Biochem 269(22):5350-5359.
47. Wang X, et al. (1998) The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways. J Biol Chem 273(16):9373-9377.
48. Morley SJ, Naegele S (2002) Phosphorylation of eukaryotic initiation factor (eIF) 4E is not required for de novo protein synthesis following recovery from hypertonic stress in human kidney cells. J Biol Chem 277(36):32855-32859.
49. Courtois-Cox S, Jones SL, Cichowski K (2008) Many roads lead to oncogene-induced senescence. Oncogene 27(20):2801-2809.
50. Coluccia AM, et al. (2007) Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 26(5):1456-1466.
51. Neviani P, et al. (2009) Activation of PP2A by FTY720 inhibits survival and self-renewal of the Ph (+) chronic myelogenous leukemia (CML) CD34+/CD38-stem cell through the simultaneous suppression of BCR/ABL and BCR/ABL-independent signals. Blood 114(22):Abstract 2168.
52. Neviani P, et al. (2005) The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8(5):355-368.
53. Kharas MG, et al. (2004) Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 103(11):4268-4275.
54. DasGupta R, Kaykas A, Moon RT, Perrimon N (2005) Functional genomic analysis of the Wnt-wingless signaling pathway. Science 308(5723):826-833.